Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Rigel Pharmaceuticals reports strong Q1 2025 growth, with revenue up 68% YoY. Learn about their $200M+ guidance, robust pipeline, and market strategy.

The aim is to make sure that foreign companies "receive the same level of regulatory oversight and scrutiny as domestic ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...